Literature DB >> 8063617

Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene.

H Ura1, T Obara, N Nishino, S Tanno, K Okamura, M Namiki.   

Abstract

Simvastatin (SV), a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, inhibits the synthesis of mevalonic acid. The dose-dependent (0.1-100 micrograms/ml) cytotoxicity of SV towards human (MIAPaCa-2, Panc-1, HPC-1, HPC-3, HPC-4, PK-1, PK-9) and hamster (T2) pancreatic carcinoma cell lines was determined by MTT assay. At up to 20 micrograms/ml of SV, the effect was reversible and was restored by 60 micrograms/ml mevalonic acid. Point mutation of Ki-ras at codon 12 in each cell line was detected by means of the modified polymerase chain reaction. The concentration of SV necessary to achieve 50% cytotoxicity was about 10 micrograms/ml, and at this concentration of SV, DNA synthesis assayed in terms of [3H]thymidine uptake, isoprenylation of p21ras examined by Western blotting and cell progression from G1 to S phase of the cell cycle analyzed by flow cytometry were all inhibited. Isoprenylation inhibitors of p21ras, such as SV, are expected to be useful for the treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8063617      PMCID: PMC5919528          DOI: 10.1111/j.1349-7006.1994.tb02406.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  22 in total

1.  Inhibition of farnesyl-protein transferase by gliotoxin and acetylgliotoxin.

Authors:  D Van der Pyl; J Inokoshi; K Shiomi; H Yang; H Takeshima; S Omura
Journal:  J Antibiot (Tokyo)       Date:  1992-11       Impact factor: 2.649

2.  Evidence for isopentenyladenine modification on a cell cycle-regulated protein.

Authors:  J R Faust; J F Dice
Journal:  J Biol Chem       Date:  1991-05-25       Impact factor: 5.157

3.  Ras proteins are essential and selective for the action of insulin-like growth factor 1 late in the G1 phase of the cell cycle in BALB/c murine fibroblasts.

Authors:  K Lu; J Campisi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 4.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

5.  Defective macromolecule biosynthesis and cell-cycle progression in a mammalian cell starved for mevalonate.

Authors:  M Sinensky; J Logel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

Review 6.  The cellular functions of small GTP-binding proteins.

Authors:  A Hall
Journal:  Science       Date:  1990-08-10       Impact factor: 47.728

7.  Cell cycle-specific effects of lovastatin.

Authors:  M Jakóbisiak; S Bruno; J S Skierski; Z Darzynkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

8.  Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and swiss 3T3 cells stimulated to divide by platelet-derived growth factor.

Authors:  A J Habenicht; J A Glomset; R Ross
Journal:  J Biol Chem       Date:  1980-06-10       Impact factor: 5.157

9.  The p21 ras C-terminus is required for transformation and membrane association.

Authors:  B M Willumsen; A Christensen; N L Hubbert; A G Papageorge; D R Lowy
Journal:  Nature       Date:  1984 Aug 16-22       Impact factor: 49.962

10.  Human lamin B contains a farnesylated cysteine residue.

Authors:  C C Farnsworth; S L Wolda; M H Gelb; J A Glomset
Journal:  J Biol Chem       Date:  1989-12-05       Impact factor: 5.157

View more
  8 in total

1.  MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.

Authors:  Lisa Koetz-Ploch; Douglas Hanniford; Igor Dolgalev; Elena Sokolova; Judy Zhong; Marta Díaz-Martínez; Emily Bernstein; Farbod Darvishian; Keith T Flaherty; Paul B Chapman; Hussein Tawbi; Eva Hernando
Journal:  Pigment Cell Melanoma Res       Date:  2017-04-19       Impact factor: 4.693

Review 2.  Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.

Authors:  Julian Swierczynski; Areta Hebanowska; Tomasz Sledzinski
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

3.  Statins and pancreatic cancer.

Authors:  Jun Gong; Esha Sachdev; Lori A Robbins; Emily Lin; Andrew E Hendifar; Monica M Mita
Journal:  Oncol Lett       Date:  2017-01-04       Impact factor: 2.967

4.  Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats.

Authors:  M Tatsuta; H Iishi; M Baba; K Iseki; H Yano; H Uehara; R Yamamoto; A Nakaizumi
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

5.  Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer.

Authors:  Sritama Nath; Lopamudra Das Roy; Priyanka Grover; Shanti Rao; Pinku Mukherjee
Journal:  Pancreas       Date:  2015-08       Impact factor: 3.327

6.  Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation.

Authors:  J J Souchek; M J Baine; C Lin; S Rachagani; S Gupta; S Kaur; K Lester; D Zheng; S Chen; L Smith; A Lazenby; S L Johansson; M Jain; S K Batra
Journal:  Br J Cancer       Date:  2014-07-15       Impact factor: 7.640

7.  Statin-induced calcification in human mesenchymal stem cells is cell death related.

Authors:  Laszlo Kupcsik; Thomas Meurya; Matthias Flury; Martin Stoddart; Mauro Alini
Journal:  J Cell Mol Med       Date:  2009 Nov-Dec       Impact factor: 5.310

8.  Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.

Authors:  T Narisawa; M Morotomi; Y Fukaura; M Hasebe; M Ito; R Aizawa
Journal:  Jpn J Cancer Res       Date:  1996-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.